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MaBACKGROUND Renin-angiotensin system activation is a feature of many cardiovascular conditions. Activity of
myocardial reduced nicotinamide adenine dinucleotide phosphate oxidase 2 (NADPH oxidase 2 or Nox2) is enhanced by
angiotensin II (Ang II) and contributes to increased hypertrophy, ﬁbrosis, and adverse remodeling. Recent studies found
that Nox2-mediated reactive oxygen species production modulates physiological cardiomyocyte function.
OBJECTIVES This study sought to investigate the effects of cardiomyocyte Nox2 on contractile function during
increased Ang II activation.
METHODS We generated a cardiomyocyte-targeted Nox2-transgenic mouse model and studied the effects of in vivo
and ex vivo Ang II stimulation, as well as chronic aortic banding.
RESULTS Chronic subpressor Ang II infusion induced greater cardiac hypertrophy in transgenic than wild-type mice
but unexpectedly enhanced contractile function. Acute Ang II treatment also enhanced contractile function in
transgenic hearts in vivo and transgenic cardiomyocytes ex vivo. Ang II–stimulated Nox2 activity increased sarco-
plasmic reticulum (SR) Ca2þ uptake in transgenic mice, increased the Ca2þ transient and contractile amplitude,
and accelerated cardiomyocyte contraction and relaxation. Elevated Nox2 activity increased phospholamban phos-
phorylation in both hearts and cardiomyocytes, related to inhibition of protein phosphatase 1 activity. In a model
of aortic banding–induced chronic pressure overload, heart function was similarly depressed in transgenic and
wild-type mice.
CONCLUSIONS We identiﬁed a novel mechanism in which Nox2 modulates cardiomyocyte SR Ca2þ uptake and con-
tractile function through redox-regulated changes in phospholamban phosphorylation. This mechanism can drive
increased contractility in the short term in disease states characterized by enhanced renin-angiotensin system
activation. (J Am Coll Cardiol 2015;66:261–72) © 2015 by the American College of Cardiology Foundation.P hysiological cardiac function requires pre-cise regulation of intracellular calcium ions([Ca2þ]i) and excitation-contraction coupling.
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ABBR EV I A T I ON S
AND ACRONYMS
Ang II = angiotensin II
[Ca2þ]i = intracellular calcium
ions
HF = heart failure
LV = left ventricular
NADPH = reduced
nicotinamide adenine
dinucleotide phosphate
NCX = sodium-calcium
exchange
Nox2 = NADPH oxidase 2
PKA = protein kinase A
PP1 = protein phosphatase 1
RAS = renin-angiotensin
system
ROS = reactive oxygen species
RyR2 = ryanodine receptor
SERCA = sarcoplasmic
reticulum Ca2D-ATPase
SR = sarcoplasmic reticulum
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262is often increased (2). However, the sources of
ROS andmechanismsof cardiomyocyte [Ca2þ]i
regulation remain elusive.
Among the sources of cellular ROS,
reduced nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (Nox) proteins
generate ROS as their primary function and
are especially important in redox signaling.
The tightly controlled and spatially conﬁned
production of low ROS levels by Nox en-
zymes is critical for their signaling function
(3). The main cardiomyocyte Nox isoforms
are Nox2 (also known as gp91phox) and Nox4;
both occur as transmembrane heterodimers
with a p22phox subunit. Nox4 is regulated
mainly by its expression level and is involved
in chronic cardiac stress responses (4). By
contrast, Nox2 is acutely activated by ago-
nists such as angiotensin II (Ang II) or me-
chanical forces in a process that involves
association with p47phox, p67phox, p40phox,
and Rac1 cytosolic subunits. Cardiac Nox2
protein levels and activity are elevated inexperimental and human HF (5,6). Previous studies
using global Nox2-null mice, p47phox-null mice, and
other models indicated that Nox2 is involved in the
development of cardiac hypertrophy, ﬁbrosis, myo-
cyte apoptosis, and ventricular remodeling induced
by Ang II, hemodynamic overload, or myocardial
infarction (7–10).SEE PAGE 273Recently, we reported a novel role of Nox2 in
regulating physiological mechanosensitive cardio-
myocyte function, dependent on the frequency and
magnitude of cardiomyocyte stretch (11,12). Physio-
logical stretch acutely activated Nox2 in the sarco-
lemma and T-tubules, and the ROS that were
generated enhanced sarcoplasmic reticulum (SR)
ryanodine receptor (RyR2) Ca2þ release and excitation-
contraction coupling. Although this mechanism may
be beneﬁcial physiologically, how elevated levels of
Nox2 affect myocyte function in disease settings
is poorly understood. Furthermore, discerning the
inﬂuences of cardiomyocyte Nox2 versus Nox2 in
other cell types (e.g., vascular, inﬂammatory) has
hitherto been difﬁcult.
Here, we generated a cardiomyocyte-targeted Nox2
transgenic mouse model to examine the effects of
elevated Nox2 levels on myocyte function. Although
Nox2 activation by chronic subpressor Ang II treat-
ment induced greater hypertrophy in the transgenic
heart, unexpectedly, in vivo cardiac function was
enhanced with Ang II treatment. Single-cell studiesdemonstrated that increases in Nox2-mediated ROS
production following Ang II stimulation promoted SR
Ca2þ-ATPase (SERCA) uptake of Ca2þ, driving in-
creased Ca2þ release and greater and more rapid
cardiomyocyte contraction and relaxation. Investi-
gation of the mechanism revealed a Nox2-dependent
increase in phospholamban phosphorylation, which
could be explained by an inhibition of protein phos-
phatase 1 (PP1) activity. These data identiﬁed a novel
mechanism in which increased Nox2 activity can
drive increased contractility during short-term Ang II
stimulation.
METHODS
Animal procedures were performed in accordance
with institutional and national standards. Transgenic
mice expressed human Nox2 complementary DNA
under control of the mouse myosin light chain
2 promoter. Transgenic mice were compared with
wild-type (WT) littermates. Left ventricular (LV)
pressure–volume analyses were performed as previ-
ously described (4).
LV cardiomyocyte sarcomere length, [Ca2þ]i tran-
sient, and voltage-clamp studies were performed as
described (11,12). SR load was quantiﬁed from mea-
surements of the sodium-calcium exchange (NCX)
current. SERCA function was estimated from the
difference in decay rates of the systolic Ca2þ and
caffeine-induced transients.
Myocardial Nox activity was assessed by lucigenin-
enhanced chemiluminescence (9). Protein phospha-
tase activity was assayed using a malachite green
assay, and PP1 activity was estimated by calyculin
A inhibition (13).
Data are mean  SE of the mean of at least 3
experiments. Comparisons were made by unpaired
Student t test and 1-way or 2-way analysis of variance
as appropriate, followed by Tukey post-hoc analysis.
A p value <0.05 was considered signiﬁcant.
For a more detailed methods summary, see the
Online Appendix.
RESULTS
BASAL PHENOTYPE IN Nox2 TRANSGENIC MICE.
NADPH oxidase activity is enhanced up to 2-fold in
both human failing myocardium and experimental
models of cardiac hypertrophy, with an increase in
the levels of Nox2 predominantly in cardiomyocytes
(5,6,10). To investigate the cardiomyocyte-speciﬁc
effects of elevated Nox2, we generated mice with
cardiomyocyte-targeted overexpression of Nox2.
Transgenic mice were born in the expected Mende-
lian ratio and bred normally. These transgenic
FIGURE 1 Cardiomyocyte-Speciﬁc Overexpression of Nox2
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(A) Protein expression in hearts of reduced nicotinamide adenine dinucleotide phosphate oxidase 2 (Nox2) transgenic (TG) mice and wild-type
(WT) littermates is seen in representative immunoblots (left) and mean data (**p < 0.01; n ¼ 3). Nox activity increased in TG versus WT hearts
after angiotensin II (Ang II) stimulation (**p < 0.01; n ¼ 4). (B) Confocal microscopy and immunostaining for Nox2 and the T-tubule/Z-line
marker Titin Z in WT and TG cardiomyocytes. Lowermost panels show high-magniﬁcation images of myocytes. Scale bars: 10 mm and 4 mm,
respectively. Fluorescence plot proﬁle from region enclosed by dotted lines shows overlay of Titin Z and Nox2 immunostaining. Ctrl ¼ control;
nNOS ¼ neuronal nitric oxide synthase; p-eNOS ¼ phosphorylated endothelial nitric oxide synthase; phox ¼ phagocyte oxidase;
Rac1 ¼ Ras-related C3 botulinum toxin substrate 1; t-eNOS ¼ total endothelial nitric oxide synthase.
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263animals had approximately 5-fold higher Nox2 pro-
tein levels in the heart (Figure 1A), whereas levels of
the Nox2 subunits p22phox, p40phox, p47phox, p67phox,
and Rac1, as well as Nox4, were similar in transgenic
and WT myocardium (Figure 1A, Online Figure 1).Nox2 colocalized with the T-tubule/Z-line marker
titin Z and exhibited additional diffuse reticular
staining in both transgenic and WT cells, but with
signiﬁcantly brighter ﬂuorescence in transgenic cells
(Figure 1B). Basal myocardial Nox activity was
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264unaltered in transgenic mice but was approximately
50% higher after Ang II stimulation than in WT mice
(Figure 1A), a similar range as that found in failing
human myocardium (5,6). The protein levels of
endothelial nitric oxide synthase and phosphorylated
(activated) endothelial nitric oxide synthase, which
can modulate ROS effects, were similar in WT and
transgenic hearts (Figure 1A, Online Figure 1). Levels
of neuronal NOS and inducible NOS were also similar.
Basal cardiac structure and function assessed by
echocardiography were unchanged in young adult
and older (12-month-old) transgenic mice (Online
Tables 1 and 2), indicating that a modest level of
Nox2 overexpression was well tolerated by the heart
in the absence of disease stimuli.
EFFECT OF IN VIVO ANG II TREATMENT. We ﬁrst
investigated the in vivo cardiac response to chronic
subpressor Ang II stimulation (0.3 mg/kg/day for 2
weeks) in WT and transgenic mice. Neither group
experienced a change in blood pressure (Online
Figure 2). Transgenic mice showed increased inter-
ventricular diastolic septal thickness, higher heart/
body weight ratio, and larger cardiomyocyte size than
WT mice after 2 weeks of Ang II (Figures 2A and 2B,FIGURE 2 Cardiac Hypertrophy and Function After Ang II Stimulatio
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ence in interstitial myocardial ﬁbrosis or myocyte
apoptosis in transgenic versus WT hearts (Online
Figure 4). Unexpectedly, transgenic mice had a
signiﬁcantly higher LV stroke volume and ejection
fraction than WT mice after 2 weeks of Ang II, without
changes in heart rate (Figure 2C, Online Figures 3B,
3C, and 3E), suggesting enhanced contractile func-
tion. To assess potential Ang II–induced increases in
contractile function, independent of concomitant LV
hypertrophy, we studied the acute in vivo effects
of Ang II (1.5 mg/kg, intraperitoneal). Measurement of
a relatively load-independent index of contractile
performance, LV maximum dP/dt (dP/dtmax)/end-
diastolic volume (14), conﬁrmed that transgenic mice
treated with Ang II developed a signiﬁcant increase in
contractility compared with WT mice (Figures 2D
and 2F). This was independent of transient Ang II–
induced changes in afterload as assessed by arterial
elastance (Online Figure 5). Transgenic mice also
showed a signiﬁcant increase in LV dP/dtmin after
acute Ang II treatment (Figures 2E and 2F), suggesting
enhanced LV relaxation.n
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265CHANGES IN MYOCYTE Ca2D SIGNALING AND
CONTRACTILITY. We next evaluated the [Ca2þ]i
transient and cell shortening in isolated LV car-
diomyocytes from WT and transgenic hearts in the
presence and absence of Ang II (1 mmol/l). Under basal
conditions, there was no difference in contractility
between groups (Figures 3A and 3B, Online Table 3). In
the presence of Ang II, transgenic myocytes showed
signiﬁcant increases in contractility and the speed of
contraction and relaxation (Figures 3A to 3D). Ang II
exerted no signiﬁcant effect on WT myocytes.
To investigate whether changes in [Ca2þ]i handling
contributed to the enhanced contractility of Ang II–
stimulated transgenic myocytes, we monitored action
potential–evoked steady state [Ca2þ]i transients.
Transgenic andWT cells showed similar global calcium
handling in the absence of Ang II. Upon Ang II stimu-
lation, however, transgenic myocytes demonstrated
increased [Ca2þ]i transient amplitude (Figures 3E and 3F)
and faster [Ca2þ]i transient decay (Figure 3H). There was
no signiﬁcant difference in the rise time of the [Ca2þ]i
transient (Figure 3G, Online Table 3).FIGURE 3 Increased Cell Contractility and [Ca2þ]i Transient in TG Ca
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tat, a peptide inhibitor speciﬁc for Nox2 (15), Ang
II’s effect on transgenic myocyte contraction and
relaxation velocities was fully blocked (Online
Figure 6, Online Table 3). These results indicated
that the measured effects in transgenic mice
were indeed due to increased Nox2-derived ROS
production.
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resenting a fundamental determinant of cardiac
relaxation and contraction (16). The faster decay of
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266elevated SR Ca2þ content, which in turn drives
increased Ca2þ release from the SR with each heart-
beat. To evaluate SERCA function and [Ca2þ]SR, we
performed voltage clamp studies. After a pre-pulse
protocol to bring the cell to steady state, a rapid
caffeine application was used to deplete SR Ca2þ
stores. Under these conditions, Ca2þ released into
the cytosol is removed by NCX, and thus integration
of the NCX current following caffeine application
was used as a precise measure of SR Ca2þ content.
Ang II stimulation of transgenic myocytes signiﬁ-
cantly elevated SR calcium content (Figures 4A
and 4B) but had no effect on [Ca2þ]SR in WT myo-
cytes. Assessment of SERCA function showed that
Ang II signiﬁcantly increased this in transgenic but
not WT myocytes, consistent with an elevation in
levels of [Ca2þ]SR (Figure 4C).
Taken together, these single-cell studies sug-
gest that increased Nox2-derived ROS production
following Ang II stimulation increases SERCA activity,
causing more rapid removal of Ca2þ from the cytosold SR Ca2þ Load and SERCA Function in TG Myocytes
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Ca2þ transient and an increase in SR Ca2þ content,
which drives increased Ca2þ release and stronger
and more rapid cardiomyocyte contraction and
relaxation, a similar pattern of change in contractile
kinetics to that found in vivo after acute Ang II
stimulation.
CHANGES IN PHOSPHOLAMBAN PHOSPHORYLATION. We
next wished to identify the mechanism responsible
for the Nox2-dependent increase in SERCA function
and enhancement of excitation-contraction coupling.
The levels of SERCA2a and total phospholamban were
unaltered in transgenic compared with WT hearts
at baseline and were unaffected by acute Ang II
stimulation (Figure 5A). However, phospholamban
phosphorylation at Ser16, the protein kinase A (PKA)–
dependent site (17), was signiﬁcantly elevated only in
transgenic hearts after Ang II treatment (Figure 5A).
There was no signiﬁcant difference between groups
in phospholamban phosphorylation at Thr17, the cal-
cium calmodulin kinase II site (16) nor in RyR2
phosphorylation at 1 common PKA phosphorylation
site (Ser2808) (18), either at baseline or after acute Ang
II stimulation (Figure 5A, Online Figure 7). Further-
more, we found no changes in the phosphorylation of
other PKA targets, such as the L-type calcium channel
and troponin I (Online Figure 8A). The level of
phospholamban Ser16 phosphorylation was also
signiﬁcantly elevated in transgenic mice treated with
2 weeks of Ang II infusion, again without changes in
other PKA targets (Online Figures 8B and 9). Taken
together, these results indicate that Ang II–stimulated
Nox2 activity speciﬁcally increased phospholamban
phosphorylation at the Ser16 PKA-dependent site
without affecting other phosphorylation sites on this
protein or affecting PKA targets in other subcellular
compartments.
To substantiate this ﬁnding, we undertook com-
plementary experiments in cultured neonatal rat car-
diomyocytes with overexpression or knockdown of
Nox2 (Online Figure 10). Stimulation with Ang II (100
nmol/l for 24 h) signiﬁcantly increased phospholam-
ban phosphorylation at Ser16 in Nox2-overexpressing
compared with beta-galactosidase–expressing con-
trol cells but had no effect on phospholamban phos-
phorylation at Thr17, RyR2 phosphorylation at Ser2808,
or SERCA2a levels (Figure 5B, Online Figure 7B).
The Ang II–stimulated increase in phospholamban
Ser16 phosphorylation in Nox2-overexpressing car-
diomyocytes was inhibited by the superoxide scav-
enger pegylated–superoxide dismutase (50 U/ml),
indicating it was ROS mediated. No Ang II–stimulated
increase in phospholamban Ser16 phosphorylation was
FIGURE 5 Nox2-Dependent Regulation of Phospholamban Phosphorylation
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267found in cardiomyocytes in which endogenous Nox2
levels were depleted (Figure 5B). To conﬁrm a role for
endogenous Nox2 in modulating phospholamban
phosphorylation in vivo, we studied the effects
of chronic Ang II infusion administered at a dose
(1.1 mg/kg/day for 2 weeks) that increased LV Nox2
protein levels by approximately 2-fold in WT mice
(Online Figure 11). We found that phospholamban
phosphorylation at Ser16 was enhanced in the Ang II–
treated WT group but attenuated in Nox2-null mice
(Online Figure 11).Because we found a Nox2-dependent increase only
in phospholamban phosphorylation at Ser16, without
concomitant changes in other potentially redox-
sensitive targets, we tested whether this effect
might involve inhibition of a phosphatase that spe-
ciﬁcally regulates this site on phospholamban, anal-
ogous to redox signaling involving other protein
targets (3,19). The serine/threonine phosphatase PP1
was a likely target because it maintains a critical role
in modulating phospholamban phosphorylation at
Ser16 (17,20). The levels of the 3 main cardiac PP1
FIGURE 6 Nox2 Inhibits PP1 Activity After Ang II Stimulation
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protein kinase A inhibition (via H89 or Rp-cAMPS) on contraction (C) and relaxation (D)
function in TG myocytes are shown. **p < 0.01 versus all other groups. Abbreviations as in
Figures 1 and 2.
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268isoforms (i.e., PP1-alpha, PP1-beta, and PP1-gamma)
were similar in WT and transgenic hearts under basal
conditions or after Ang II treatment (Figure 6A, Online
Figure 12). However, PP1 activity was signiﬁcantly
decreased after Ang II treatment in transgenic hearts
compared with WT (Figure 6B).
To conﬁrm that Nox2-mediated modulation of
contractile function is dependent on PKA activation,
we studied the effects of 2 different PKA inhibitors,
H89 and Rp-cAMPS. The enhanced Ang II–stimulated
contractile state in transgenic myocytes was com-
pletely blocked by either inhibitor (Figures 6C and 6D).
These inhibitors exerted no effect in WT myocytes
(Online Figure 13).
RESPONSE TO CHRONIC PRESSURE OVERLOAD IN
TRANSGENIC MICE. To evaluate increased Nox2 ac-
tivity in a setting of more severe disease stress, we
next subjected transgenic and WT mice to chronic
abdominal aortic banding (3 weeks). Similar to Ang IItreatment, this pressure overload induced greater
hypertrophy in transgenic than WT mice (Online
Figure 14A). However, compared with WT, trans-
genic mice trended toward poorer cardiac function
(Online Figures 14B to 14D). Interestingly, immuno-
blot analyses showed that although transgenic/
banded mice had higher levels of phospholamban
phosphorylation at Ser16 than WT/banded mice, the
levels were signiﬁcantly reduced compared with
respective sham controls (Online Figure 14E). SER-
CA2a protein levels were similar among groups
(Online Figure 14E). The data therefore suggest that
although Nox2-induced activation of phospholamban
phosphorylation enhances short-term contractile
function, in the setting of chronic overload stress, a
sustained increase in cardiomyocyte Nox2 activity
eventually leads to exaggerated cardiac remodeling.
DISCUSSION
In this study, Ang II–stimulated Nox2-ROS production
augmented cardiac contractile performance by
increasing SERCA function and driving more rapid
Ca2þ reuptake and enhanced Ca2þ release, thereby
causing faster contraction and relaxation. These ef-
fects were attributable to inhibition of PP1 activity
and increased phospholamban phosphorylation
(Central Illustration). Although the chronic effects of
Nox2 activation on cardiac hypertrophy and remod-
eling are well recognized, here we identiﬁed a novel
mechanism through which enhanced Nox2 activation
may acutely beneﬁt cardiac contractile function.
Myocardial ROS are generated in increased
amounts during renin-angiotensin system (RAS)
activation. The pathophysiological effects of ROS
include those mediated by redox signaling (i.e., the
speciﬁc, usually reversible, oxidation-reduction of
components of cellular signaling pathways) (19). As
dedicated ROS generators, Nox proteins are particu-
larly important in redox signaling. Previous work
showed that cardiomyocyte Nox2 expression and the
level of myocardial Nox activity are signiﬁcantly
elevated in experimental models of hypertension and
human chronic HF (5,10,21,22), conditions associated
with RAS activation. Studies using global Nox2-null
mice found that Nox2-mediated redox signaling
plays an important role in Ang II–mediated and post–
myocardial infarction cardiac hypertrophy and
adverse remodeling. Because Nox2 is expressed in
multiple cell types (e.g., cardiomyocytes, endothelial
cells, ﬁbroblasts, inﬂammatory cells, neurons, renal
cells), its cell-speciﬁc effects remain unclear.
Here, we developed a new mouse model with a
cardiomyocyte-targeted increase in Nox2 expression
CENTRAL ILLUSTRATION Nox2 and Myocyte Phospholamban Phosphorylation
Zhang, M. et al. J Am Coll Cardiol. 2015; 66(3):261–72.
Activation of reduced nicotinamide adenine dinucleotide phosphate oxidase 2 (Nox2) by angiotensin II (Ang II) leads to the inhibition of protein
phosphatase 1 (PP1), thereby promoting an increase in protein kinase A (PKA)–dependent phospholamban (PLN) phosphorylation. This in turn
promotes increased uptake of calcium ions (Ca2þ) via the sarcoplasmic reticulum (SR) Ca2þ ATPase (SERCA), increased SR Ca2þ load, and
increased Ca2þ release through ryanodine receptors (RyR2). The result is an increase in amplitude of Ca2þ transient and twitch contraction and
faster contraction and relaxation in Nox2 transgenic (TG) compared with wild-type (WT) cardiomyocytes. Ca ¼ calcium; [Ca2þ]i ¼ intracellular
calcium concentration; ROS ¼ reactive oxygen species; S16 ¼ serine 16.
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270and deﬁnitively demonstrated that cardiomyocyte
Nox2 is involved in the development of Ang II–
induced hypertrophy in vivo. The increase in Ang
II–stimulated NADPH oxidase activity in transgenic
hearts was in a pathophysiologically relevant range
(5,6) and Nox2 overexpression was not accompanied
by confounding changes in Nox4 levels. No signiﬁ-
cant phenotype was found in transgenic hearts in the
absence of Ang II stimulation, even at age 12 months,
consistent with the fact that Nox2 is quiescent unless
activated by speciﬁc agonists.
In studying the effects of 2 weeks of subpressor
Ang II treatment on cardiac function, we made the
unanticipated ﬁnding that contractile function was
enhanced in transgenic animals. To distinguish be-
tween the effects of cardiac hypertrophy and changes
in contractile function, we assessed the acute in vivo
response of transgenic mice to Ang II by invasive
pressure-volume analysis and found that this was
also signiﬁcantly enhanced. This load-independent
analysis suggests Ang II had intrinsic positive
inotropic effects on transgenic myocardium, which
was conﬁrmed by studies in isolated cardiomyocytes.
Therefore, increased cardiomyocyte Nox2 activation
signiﬁcantly augmented the acute contractile
response to Ang II. The acute effects of Ang II on
normal myocardium vary, with studies reporting
positive (23), negative (24), or no inotropic effect
(25), probably related to temporal, concentration-
dependent, and species differences. We found mini-
mal acute inotropic effects of Ang II in healthy, young
adult mouse cardiomyocytes and intact hearts.
However, when the capacity for Nox2-dependent ROS
production was increased, as occurs in disease set-
tings (10), Ang II had signiﬁcant positive inotropic
and lusitropic effects.
Changes in intracellular redox state may inﬂu-
ence excitation-contraction coupling either through
oxidative modiﬁcations of speciﬁc Ca2þ handling
proteins (e.g., RyR2, SERCA2a) or via redox-
mediated changes in activity of protein kinases
that regulate Ca2þ-handling proteins (2,19). Such
modiﬁcations have rarely been linked mechanisti-
cally to speciﬁc ROS sources. However, the recent
ﬁnding of stretch-evoked Nox2-mediated regulation
of RyR2 Ca2þ release in normal cardiomyocytes
(termed “X-ROS signaling”) established a new para-
digm for redox modulation of excitation-contraction
coupling, by linking the ROS effect to speciﬁc stim-
ulation of a distinct ROS source. In the current
study, we found a conceptually similar but mecha-
nistically quite different modulation in a disease
setting. Here, the speciﬁc activation of Nox2 by Ang
II resulted in increased SERCA activity driven byenhanced phospholamban phosphorylation and led to
enhanced contraction and relaxation.
The mechanism of Nox2-mediated increase in
SERCA activity was an increase in phospholamban
phosphorylation at a PKA-dependent site. Interest-
ingly, we did not ﬁnd signiﬁcant changes in the
phosphorylation of other PKA targets, such as the
L-type calcium channel and troponin I nor in
the target of redox-activatable calcium-calmodulin
kinase II on the phospholamban Thr17 site, suggesting
a compartmentalized effect within the cardiac myo-
cyte. An attractive mechanism for such an effect is the
local redox inactivation of a phosphatase that regu-
lates phospholamban phosphorylation, similar to
mechanisms involved in redox enhancement of re-
ceptor phosphorylation (26,27). The most likely
candidate for such a mechanism was PP1, which
speciﬁcally regulates phospholamban phosphoryla-
tion (20). Indeed, we found that PP1 activity was
robustly inhibited in Ang II–treated transgenic mice,
consistent with a mechanism in which Nox2 in-
activates PP1, allowing for an increase in phospho-
lamban phosphorylation. This mechanism was
further conﬁrmed when PKA inhibitors completely
blocked Ang II–mediated enhancement of contractile
function in transgenic myocytes.
The precise spatial interrelationship between
Nox2, PP1, and phospholamban, or how PP1 is
inhibited by Nox2, remains speculative at this stage.
Previously, Nox2 was found to be located at the T-
tubules (11); we observed a similar localization
pattern in transgenic myocytes in the current study
(i.e., a location that is relatively distant on the cellular
scale of ROS signaling from phospholamban and
SERCA at the network SR). It is possible that Nox2
inhibits PP1 locally at the junctional SR and this then
transduces the signal to phospholamban at the
network SR. Alternatively, there may be distinct
subcellular pools of Nox2, with the effects on phos-
pholamban phosphorylation potentially mediated by
Nox2 at the network SR. Interestingly, immuno-
staining for Nox2 indicated both a T-tubule and a
diffuse reticular pattern that could be consistent with
the latter possibility.
A Nox2-mediated increase in contractile function
during enhanced RAS activation may hold clinical and
therapeutic implications. Whereas ROS-mediated ef-
fects are usually considered detrimental in disease
settings, here we identiﬁed a novel mechanism that
could maintain contractile function, at least in the
relative short term. It is interesting to speculate
whether the hypotensive effects observed upon
initiating angiotensin-converting enzyme inhibitors
may, at least in part, be related to loss of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The impact of
RAS activation on end-organ structure and function involves
several signaling pathways, including the ROS-generating
enzyme Nox2. The adverse cardiac remodeling associated with
elevated levels of Ang II is partly mediated by activation of Nox2,
but Nox2 activation can also enhance myocardial contractile
function though effects on calcium transport.
TRANSLATIONAL OUTLOOK: Additional studies are needed
to determine whether various drugs that inhibit the RAS exert
different acute negative inotropic effects mediated by reduction
in Nox2 activity.
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271Nox2-mediated positive inotropic activity. To assess
the impact of Nox2-dependent changes in contractile
function in a more severe and chronic setting, we
studied the effects of chronic abdominal aortic band-
ing, an intervention that not only induces pressure
overload but also increases RAS activation (28). Inter-
estingly, although phospholamban phosphorylation
was greater in transgenic compared with WT mice, as
in the Ang II infusion model, cardiac remodeling and
function were, if anything, worse in transgenic mice
after aortic banding.
STUDY LIMITATIONS. The inotropic effects of Nox2-
mediated increases in SERCA function and SR Ca2þ
release may be outweighed in longer-term settings of
pressure overload cardiac hypertrophy, and this re-
quires further study. Nevertheless, the current ﬁnd-
ings suggest that RAS activation may be accompanied
by beneﬁcial acute contractile effects related to
increased myocardial Nox2 activation.
CONCLUSIONS
We identiﬁed a novel mechanism in which Nox2
modulates cardiomyocyte SR Ca2þ uptake and con-
tractile function through redox-regulated changes in
phospholamban phosphorylation. This mechanism
can drive increased contractility, in the short term,in disease states characterized by enhanced RAS
activation. A Nox2-mediated increase in contractile
function during enhanced RAS activation may have
clinical and therapeutic implications.
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